Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Benlysta · 1 trial · 1 indication
Number of participants with presence and size of induration in active versus control at the Candin injection site compared to the intra-individual saline control injection site approximately 48 hours after Candin challenge will be reported.
| Arm | Type | Description |
|---|---|---|
| Active Arm: Benlysta + Candin | ACTIVE_COMPARATOR | Participants will receive a single dose of Candin injection intradermally along with a saline solution of 0.9% sodium chloride (NaCl), and a single dose of Benlysta injection subcutaneously. |
| Control Arm: Candin | NO_INTERVENTION | All participants will receive a single dose of Candin injection intradermally along with a single dose of saline solution of 0.9% NaCl administered intradermally and no Benlysta. |
| Name | Type | Description |
|---|---|---|
| Benlysta | DRUG | Benlysta injection will be administered subcutaneously. |
| Candin | DRUG | Candin will be administered intradermally along with NaCl solution. |
Inclusion Criteria: * Have a body mass index (BMI) between 18.0 and 30.0 kilogram per meter square (kg/m\^2, inclusive (BMI = weight/height\^2), and body weight of no less than 50 kilograms (kg) * Healthy on the basis of physical examination, medical history, and vital signs performed at screening....
Benlysta is an investigational small molecule being developed by Johnson & Johnson (JNJ). It is currently in Phase 1 clinical development. The drug is being studied in healthy participants, and its therapeutic area is classified as Other.
Benlysta is being studied for use in healthy participants. It is currently in Phase 1 clinical development, and the specific condition it is intended to treat has not been established. The drug is being evaluated in a clinical trial involving healthy volunteers.
Benlysta is being developed by Johnson & Johnson, a company traded on the stock exchange under the ticker symbol JNJ. The drug is currently in Phase 1 clinical development.
Benlysta is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a clinical trial involving healthy participants.
Benlysta is associated with one completed clinical trial, NCT04611971, titled "A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2." This Phase 1 trial enrolled 13 participants in Belgium and was active-controlled.